Top Biotech Companies To Buy For 2014

If Celgene (CELG) were a Beach Boy, it would be David Marks, who left the band and missed out on all the fun.

This year, Celgene has dropped 9.9%, even as other giant biotech companies like Biogen Idec (BIIB), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) has gained 7% or more. Even the SPDR S&P Biotech ETF (XBI) has managed to stay above water despite big March losses.

Part of Celgene’s weakness can be attributed to the battle over Revlimid, which is facing a patent challenge. UBS analyst Matthew Roden and team explain why they’re sticking with Celgene:

We spoke to the company and a legal expert following the Markman order this week, and continue to believe that a 2025-27 Revlimid patent duration is likely (which in our opinion is not priced in). Our Buy thesis on Celgene is unchanged, as it trades at a considerable discount to its DCF until the legal case is resolved 2014-1H15e, as well as other catalysts that we believe can drive upside to
numbers…

Top 5 Performing Stocks For 2015: Synergy Pharmaceuticals Inc (SGYP)

Synergy Pharmaceuticals, Inc., incorporated on February 11, 1992, is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�� lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�� active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors.

As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor. As of December 31, 2011, the Company was dosing patients in an 800-patient Phase II/III clinical trial of plecanatide to treat. It is also developing a second generation GC-C receptor analog, SP-333, which is in pre-clinical development for the treatment of gastrointestinal inflammatory diseases. SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone.

The Company competes with Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., Takeda Pharmaceuticals America, Inc., Sucampo Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and Shire Plc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.

  Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top Biotech Companies To Buy For 2014: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:

• [By Dan Caplinger]

  In addition to General Electric's big gains for the day after reporting earnings, pharma stocks Johnson & Johnson (NYSE: JNJ  ) and Pfizer (NYSE: PFE  ) both posted nice gains of more than 2%. For J&J, an analyst downgrade of rival Merck yesterday highlighted the competitive threat that J&J's Invokana diabetes drug could pose to its existing blockbuster Januvia. With high hopes for Invokana, if J&J can tap into a portion of the billions of dollars that Januvia has brought in over the years, it could create a meaningful boost in earnings, even for a company of J&J's size. Meanwhile, Pfizer reportedly decided not to try to outbid Amgen for cancer-drug producer Onyx Pharmaceuticals, even as investors in Onyx have bid the shares well beyond Amgen's original $120 offer. Buying promising pipelines is a valid strategy, but having the discipline not to overpay is essential, and shareholders are right to reward Pfizer today.

• [By Peter Stephens]

  Johnson & Johnson� (NYSE: JNJ  ) �is often cited as the biggest pharmaceutical company in the world, but it also generates a significant amount of revenue from medical device products. Let's take a deep dive into this division and focus on the key areas that investors should watch.

• [By Brian Orelli]

  Pfizer's blood thinner, Eliquis, was approved late last year. The drug, which Pfizer sells with Bristol-Myers Squibb (NYSE: BMY  ) , has multibillion-dollar potential because the current offering, warfarin, is difficult to use. While doctors are clamoring for a replacement, drugmakers developed three. In addition to Eliquis, there's also Johnson & Johnson's (NYSE: JNJ  ) Xarelto and Boehringer Ingelheim's Pradaxa. The blood thinner market is so large, I think there's plenty of room for all three.

Top Biotech Companies To Buy For 2014: Foundation Medicine Inc (FMI)

Foundation Medicine, Inc., incorporated on November 12, 2009, is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated. The Company�� platform includes methods and algorithms for analyzing tumor tissue samples across all types of cancer, as well as information aggregation and concise reporting capabilities. Its products provide genomic information about each patient�� individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively.

FoundationOne, its first clinical product, is, to its knowledge, the only commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer. In addition, the Company is considered a non-contracting provider by commercial third-party payors because it has not entered into specific contracts to provide FoundationOne to their covered patients, and as a result it takes on primary responsibility for obtaining reimbursement on behalf of patients.

Advisors' Opinion:

• [By John Udovich]

  If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

• [By John Udovich]

  Small cap healthcare information stocks Everyday Health Inc (NYSE: EVDY), Foundation Medicine Inc (NASDAQ: FMI) and CollabRx Inc (NASDAQ: CLRX) help consumers and healthcare professionals deal with the increasing amount of information overload that comes with treating or figuring out how to treat patients.

• [By James E. Brumley]

  It wouldn't be fair to say there's nothing like it "out there", because there is. A company called Foundation Medicine Inc. (NASDAQ:FMI) has developed a similar/comparable app. The CLRX version of the solution appears superior in most ways, however, if for no other reason than because of the projected revenue growth the company is apt to see.

Top Biotech Companies To Buy For 2014: Redpoint Bio Corp (RPBC)

Redpoint Bio Corporation (Redpoint), incorporated in August 1995, is a development-stage biotechnology company. The Company leverages discoveries in the molecular biology of taste to discover and develop taste modulators for the food and beverage industries. Its food and beverage program has been focused on identifying flavor modifiers that improve the taste of ingredients. In June 2009, the Company announced that it had identified an all-natural sweetness enhancer, RP44. RP44 is Reb-C (rebaudioside C), a component of the stevia plant.

Sweetness Enhancer Program

Redpoint announced that it had identified RP44, an all-natural sweetness enhancer, in June 2009. In January 2010, it disclosed that RP44 is Reb-C (rebaudioside C), a component of the stevia plant. RP44 is derived from material found in the side stream of the Reb A production process. A purified component of stevia known as Reb A has received regulatory approval in the United States. Unlike Reb A, RP44 has a low intrinsic level of sweetness and therefore is not useful as a sweetener.

Diabetes and Obesity Drug Discovery Program

The Company�� initial programs focused on the modulation of the TRPm5 ion channel, a signaling element in taste sensation, in order to discover compounds that modulate the taste of food and beverage products. Redpoint initiated a program designed to leverage the research it had already conducted on the discovery of modulators of the TRPm5 ion channel to further explore opportunities for the discovery of diabetes or obesity therapeutics. TRPm5 modulators discovered at Redpoint have been shown to elicit the secretion of hormones known to play roles in metabolism in relevant model systems.

The Company competes with International Flavors & Fragrances Inc., Givaudan SA, Symrise, Firmenich, Senomyx, PureCircle Ltd, GLG Life Tech Corporation, Eli Lilly and Company, Amylin Pharmaceuticals, Merck & Co., Inc., Metabolex, Inc., OSI Pharmaceuticals, GlaxoSmithKline! , Arena Pharmaceuticals, Inc. and Johnson & Johnson.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check: